晚期糖化终产品的受体在冠状动脉中多态
Ezgi Irmak Aslan1, Gulcin Ozkara2, Onur Kilicarslan3
1Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey; Department of Medical Biochemistry, Faculty of Medicine, Istanbul Nisantasi University, Istanbul, Turkey.
Gene
|April 8, 2024
概括
先进的糖化终产品 (RAGE) -374A等位体的受体与冠状动脉脱血 (CAE) 的风险增加有关. 这一遗传因素与CAE患者年龄较小和血小板数量较高有关.
科学领域:
- 心血管遗传学 心血管遗传学
- 分子心脏病学分子心脏病学
- 遗传流行病学遗传流行病学
背景情况:
- 已知先进糖化最终产品 (RAGE) 的受体在冠状动脉疾病中的参与,但其在冠状动脉抽血 (CAE) 中的作用尚不清楚.
- 雷格多态对溶性雷格 (sRAGE) 水平的影响需要进一步定义.
研究的目的:
- 调查RAGE -374T>A (rs1800624) 和G82S (rs2070600) 功能多态对CAE发展的影响.
- 探索这些RAGE多态,sRAGE水平和CAE患者的临床特征之间的关联.
主要方法:
- 对2452名接受冠状动脉血管造影的患者进行前性观察性研究.
- 使用实时PCR进行RAGE -374T>A和G82SSNP的基因定型.
- 通过ELISA测定血清sRAGE和sOLR1;测量血清脂质.
主要成果:
- 在CAE患者中,RAGE -374A等位基因和 -374AA基因型的发生频率明显高 (p < 0.001).
- 在CAE患者中,可溶性莱克类氧化受体-1 (sOLR1) 水平升高 (p = 0.004).
- -374A基因组与CAE患者的年龄较小和血小板数量较高相关,并被确定为CAE的危险因素.
结论:
- RAGE -374A等位基因与CAE的风险增加有关,可能与血小板激活有关.
- 抗高血压和抗糖尿病治疗可能会增加CAE患者的sRAGE水平.
- 需要进一步的大规模研究来证实这些关于RAGE多态性和CAE病变的发现.
相关概念视频
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:09GPCRs Regulate Adenylyl Cylase Activity
5.5K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.5K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
156
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
156